MEN1 Syndrome and Pancreatic NETs: When Genetics Changes Everything About Your Risk

15 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Discover how MEN1 syndrome dramatically increases your risk of pancreatic neuroendocrine tumors (NETs), with up to an 80% lifetime chance for mutation carriers. Learn about early onset, multifocal tumors, genetic testing importance, family screening protocols, and tailored management strategies like observation versus surgery for tumors under 2 cm. This video explains differences from sporadic NETs, surveillance guidelines, and actionable steps for patients and families.

This content is entirely based on medical research and evidence, carefully curated by Mr Saboor Khan PhD FRCS FACS (Consultant Surgeon).

00:00 Introduction
01:00 What is MEN1 Syndrome?
02:00 Genetic Risk is Substantial - 80% Lifetime Chance
03:20 MEN1 Tumors Start Earlier and Behave Differently
04:40 Genetic Testing Changes Management
05:55 Family Screening Protocols
07:05 When to Operate Versus Observe
08:25 Understanding Natural History
09:30 Action Steps and Resources


Explore the full video series in our playlist for a broader understanding of your condition with evidence-based content.

Educational Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Personal medical decisions must be made in consultation with your treating healthcare team. Patients should not draw inferences about their own condition from this general information. Every effort has been made to ensure the content is current at the time of production; however, medical knowledge evolves and this cannot be guaranteed.
Categoria
Oncology
Commenta per primo questo video.

Prossimo